Phase II study of fazarabine in advanced head and neck cancer. A Southwest Oncology Group study.
Kuebler
J P
JP
University of Oklahoma Health Center, Oklahoma City.
Metch
B
B
Schuller
D E
DE
Keppen
M
M
Hynes
H E
HE
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000627:therapeutic use* / Q000031:analogs & derivatives; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; C022121:fazarabine; D001374:Azacitidine